Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
In an effort to provide customers additional benefits through its over-the-counter (“OTC”) facilities, CME Group Inc. ( CME - Analyst Report ) is making arrangements to offer “clearing services” for London silver forward contracts, according to a Reuters report. On receiving approval of the regulatory bodies, the program is scheduled to start from August 5, followed by trading on the next day.
Experts opine that this initiative by the company follows the sharp fall in trading volumes of silver traded in the exchange. According to CME reports, silver futures volumes plunged 41% from $12.02 billion during the first-half of 2012.
The fall in silver futures volume is in stark contrast to the rise in trading volumes of gold and copper futures by 2.5% and 50%, respectively. In addition, gold and copper are the most popularly traded metals on the exchange.
CME Group’s decision to launch the OTC clearing services comes at a time when the commodities market is facing turbulence, owing to the MF Global Holdings fiasco and mismanagement of “customers' segregated funds.”
However, the demand for silver has been on the upswing following the deterioration of the U.S. Dollar and other pressing issues prevalent in the Middle East.
CME holds a 98% share of U.S. futures, trading with a clearing house notional value of over $35 trillion. The company’s launch of metal contracts along with OTC interest rate swaps and cross-margining between CME Clearing Europe and its U.S. clearing house in the first half of 2012 has further accentuated its global presence. Most of CME Group’s long-term growth investments have shown favorable upsides.
CME Group currently retains a Zacks #3 Rank, which translates into a short-term Hold rating. It competes closely with IntercontinentalExchange, Inc. ( ICE - Analyst Report ) , which has a similar Zacks rank. We also maintain a long-term Neutral rating on CME Group’s shares.
Read the full Analyst Report on CME
Read the full Analyst Report on ICE